Small Trial Tests Interleukin-6 Blocker for Depression
A pilot study examined whether an anti-inflammatory drug could reduce symptoms in people with depression. The placebo-controlled randomized trial involved a small number of participants.
rnz.co.nzA small pilot study tested whether an interleukin-6 blocker, an anti-inflammatory drug, could affect symptoms of depression. The trial was placebo-controlled and randomized. Researchers reported that the approach might be possible based on early results.
The trial used a placebo group for comparison.
It was described as a pilot study with a limited number of participants. Further research would be needed to assess whether the findings hold in larger groups.
Key Facts
Potential Impact
- 01
Larger trials may be conducted to confirm any effect on depression symptoms.
Transparency Panel
Related Stories
NprWHO Director Visits Congo as Ebola Outbreak Spreads
The head of the World Health Organization arrived in Kinshasa to support efforts against a rare Ebola strain. Health workers face equipment shortages, community distrust, and armed conflict in affected provinces.
medpagetoday.comFDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
Benzinga Publishes Article on Biotech Stocks During Pandemic Recovery
Benzinga published an article titled 'Best Biotech Stocks Right Now' that addresses the sector's position during global recovery from the pandemic. The piece notes government institutions and professional traders are focusing on biotech companies for vaccine and booster developme…